Sign in to view content

APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies

Michael J Allingham, MD, PhD

Video
Published 2021

Related

Real-World Evidence for Pneumatic Retinopexy in Patients With Primary Rhegmatogenous Retinal Detachment Meeting PIVOT Trial Criteria
Verena Juncal, MD
Annual Meeting Talks
2019
Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study
Eric W Schneider, MD
Updates from the Field
2025
Protocol T Extension Results
John A. Wells, MD, FACS
Updates from the Field
2019

Category: Diabetic Retinopathy

See more